Effects of trimetazidine on ischemic left ventricular dysfunction in patients with coronary artery disease.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  American Journal of Cardiology

• Publication date

  1998-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0002-9149(98)00500-1PMID 9781975
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mechanism of action of a novel metabolically active antianginal agent (trimethazidine) delineated by PET

  1996cited by this paper
• Combination therapy of trimetazidine with diltiazem in patients with coronary artery disease. Group of South of France Investigators.

  1995cited by this paper
• Improvement of long-term preservation of the isolated arrested rat heart by trimetazidine: effects on the energy state and mitochondrial function.

  1995cited by this paper
• Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Trimetazidine European Multicenter Study Group.

  1994cited by this paper
• Some biochemical aspects of the protective effect of trimetazidine on rat cardiomyocytes during hypoxia and reoxygenation.

  1994cited by this paper
• Comparison of trimetazidine with nifedipine in effort angina: A double-blind, crossover study

  1990cited by this paper
• Beneficial effects of trimetazidine in men with stable agina under beta-blocker treatment

  1989cited by this paper
• Anti-ischemic effects of trimetazidine: 31P-NMR spectroscopy in the isolated rat heart.

  1987cited by this paper
• [Effectiveness of trimetazidine in stable effort angina due to chronic coronary insufficiency. A double-blind versus placebo study].

  1986cited by this paper
• Effect of trimetazidine on membrane damage induced by oxygen free radicals in human red cells.

  1985cited by this paper

• Trimetazidine Use in Cardiovascular Disease.

  2025cites this paper
• Metabolic intervention with trimetazidine improves intracardiac hemodynamics and reduces re-hospitalizations in patients with advanced heart failure.

  2025cites this paper
• Regenerative therapies for myocardial infarction: exploring the critical role of energy metabolism in achieving cardiac repair

  2025cites this paper
• Regulatory effects of trimetazidine in cardiac ischemia/reperfusion injury

  2023cites this paper
• Effect of Glucose-Insulin-Potassium infusion on systolic and diastolic functions in patients with chronic ischemic cardiomyopathy

  2021influential citation
• A különféle trimetazidinkészítmények klinikai hatása stabil anginával járó krónikus koszorúér-szindrómában Frissített módszeres áttekintés és metaanalízis Clinical effect of various trimetazidine formulations in chronic coronary syndrome An

  2020cites this paper
• [Clinical effect of various trimetazidine preparations in chronic coronary syndrome with stable angina. Updated systematic review and meta-analysis].

  2020cites this paper
• Clinical efficacy and safety of trimetazidine as an add-on with standard therapy in patients with coronary artery disease of South India

  2020cites this paper
• Für Sie gelesen: Efficacy Comparison of Trimetazidine with Therapeutic Alternatives in Stable Angina Pectoris: A Network Meta-Analysis

  2019cites this paper
• Baminger Effi cacy Comparison of Trimetazidine with Therapeutic Alternatives in Stable Angina Pectoris : A Network Meta-Analysis

  2019cites this paper
• Metabolic Modulation of Cardiac Metabolism in Heart Failure.

  2018cites this paper
• Effi cacy Comparison of Trimetazidine with Therapeutic Alternatives in Stable Angina Pectoris : A Network Meta-Analysis

  2018cites this paper
• Trimetazidine and Other Metabolic Modifiers.

  2018cites this paper
• WITHDRAWN: Trimetazidine for stable angina.

  2017cites this paper
• Assessment of Metabolic Therapy for Acute Heart Failure

  2017cites this paper
• Pharmacological Agents Targeting Myocardial Metabolism for the Management of Chronic Stable Angina : an Update

  2016cites this paper
• Harnessing Cardiac Energetics in the Treatment of Heart Failure

  2016cites this paper
• Congenital Aortic Stenosis in a Fetus: A Case Report and Review of Syndromic Associations

  2016cites this paper
• EFFECTS OF THERAPY WITH TRIMETAZIDINE IN ISCHEMIC HEART DISEASE

  2016cites this paper
• Trimetazidine improves exercise tolerance in patients with ischemic heart disease

  2016cites this paper
• Trimetazidine does not alter metabolic substrate oxidation in cardiac mitochondria of target patient population

  2016cites this paper
• Effects of sustained-release trimetazidine on chronically dysfunctional myocardium of ischemic dilated cardiomyopathy – Six months follow-up result

  2016cites this paper
• Rationale and benefits of trimetazidine by acting on cardiac metabolism in heart failure.

  2016cites this paper
• Targeting Mitochondrial Dysfunction in Chronic Heart Failure: Current Evidence and Potential Approaches.

  2016cites this paper
• Metabolic efficiency in remodeled failing hearts

  2015cites this paper
• Metabolic approach to heart failure: The role of metabolic modulators

  2015cites this paper
• Metabolic Therapy in Heart Failure.

  2015cites this paper
• Deranged Cardiac Metabolism and the Pathogenesis of Heart Failure.

  2015cites this paper
• Trimetazidine and Cardioprotection

  2015cites this paper
• Aldose Reductase and Diabetic Cardiovascular Disease

  2014cites this paper
• Guideline for stable coronary artery disease.

  2014cites this paper
• Defining the Role of Trimetazidine in the Treatment of Cardiovascular Disorders: Some Insights on Its Role in Heart Failure and Peripheral Artery Disease

  2014cites this paper
• Modulation of Myocardial Metabolism by 3-Ketoacyl Coenzyme a Thiolase Inhibition and Other Agents in Heart Failure Treatment

  2014cites this paper
• Effects of trimetazidine in nonischemic heart failure: a randomized study.

  2014cites this paper
• Trimetazidine MR improves survival of coronary patients

  2013cites this paper
• Effect of partial fatty acid oxidation inhibition with trimetazidine on mortality and morbidity in heart failure: results from an international multicentre retrospective cohort study.

  2013cites this paper
• New pharmacological targets in the treatment of heart failure: inhibition of free fatty oxidation by trimetazidine

  2012cites this paper
• The improvement of trimetazidine on exercise performance in ischemic heart disease

  2012cites this paper
• Effect of partial inhibition of fatty acid oxidation by trimetazidine on whole body energy metabolism in patients with chronic heart failure

  2011cites this paper
• Efficacy Comparison of Trimetazidine with Therapeutic Alternatives in Stable Angina Pectoris: A Network Meta-Analysis

  2011cites this paper
• Beneficial effects of trimetazidine (Vastarel ® MR) in patients

  2011cites this paper
• Metabolic Modulation: A New Therapeutic Target in Treatment of Heart Failure

  2011cites this paper
• Metabolic remodelling in human heart failure.

  2011cites this paper
• New therapeutic approaches Metabolic modulation in dilated cardiomyopathy

  2011cites this paper
• Pharmacological strategies against cold ischemia reperfusion injury

  2010cites this paper
• Metabolic modulation in dilated cardiomyopathy

  2010cites this paper
• [Acute coronary syndrome with ST segment depression on ECG: novel outlook of an old problem].

  2010cites this paper
• Beneficial Electrophysiological Effects of Trimetazidine in Patients With Postischemic Chronic Heart Failure

  2010cites this paper
• Role of Metabolic Modulation in the Management of chronic Ischemic Heart Disease

  2010cites this paper
• Clinical overview of trimetazidine (Vastarel MR) in patients with heart failure

  2010cites this paper
• Comparison of exercise electrocardiography, technetium-99m sestamibi single photon emission computed tomography, and dobutamine and dipyridamole echocardiography for detection of coronary artery disease in hypertensive women.

  2010cites this paper
• The metabolic treatment of patients with coronary artery disease: effects on quality of life and effort angina.

  2009cites this paper
• Cardiovascular drug development using radiopharmaceuticals.

  2009cites this paper
• Effects of metabolic approach in diabetic patients with coronary artery disease.

  2009cites this paper
• Effect of Antianginal Drugs in Stable Angina on Predicted Mortality Risk after Surviving a Myocardial Infarction

  2009cites this paper
• Improved left and right ventricular functions with trimetazidine in patients with heart failure: a tissue Doppler study

  2009cites this paper
• This material is the copyright of the original publisher. Unauthorised copying and distribution is prohibited. Effect of Antianginal Drugs in Stable Angina on Predicted Mortality Risk after Surviving a Myocardial Infarction A Preliminary Study (METRO)

  2009cites this paper
• Metabolic therapy of heart failure.

  2008cites this paper
• Early Metabolic Intervention in the Management of Coronary Artery Disease

  2008cites this paper
• The role of trimetazidine after acute myocardial infarction.

  2008cites this paper
• Trimetazidine revisited: a comprehensive review of the pharmacological effects and analytical techniques for the determination of trimetazidine.

  2008cites this paper
• Trimetazidine, a Metabolic Modulator, Has Cardiac and Extracardiac Benefits in Idiopathic Dilated Cardiomyopathy

  2008cites this paper
• Modulation of fatty acids oxidation in heart failure by selective pharmacological inhibition of 3-ketoacyl coenzyme-A thiolase.

  2007cites this paper
• Trimetazidine and Reduction in Mortality and Hospitalization in Patients With Ischemic Dilated Cardiomyopathy: A Post Hoc Analysis of the Villa Pini D'Abruzzo Trimetazidine Trial

  2007cites this paper
• Inhibition of free fatty acids metabolism as a therapeutic target in patients with heart failure

  2007cites this paper
• The role of trimetazidine in heart failure

  2007cites this paper
• The effect of trimetazidine on left ventricular systolic function and physical tolerance in patients with ischaemic cardiomyopathy

  2007cites this paper
• New directions in the treatment of heart failure: Targeting free fatty acid oxidation

  2007cites this paper
• Zmniejszenie dolegliwoúci d‡awicowych, wzrost tolerancji wysi‡ku oraz poprawa perfuzji i funkcji lewej komory serca po leczeniu trimetazydyn"

  2007cites this paper
• Metabolic Management of Coronary Artery Disease ( CAD ) 85 16 Metabolic Management of Coronary Artery Disease ( CAD )

  2007cites this paper
• Trimetazidine to reverse ischemia in patients with class I or II angina: a randomized, double-blind, placebo-controlled dobutamine–atropine stress echocardiography study

  2007cites this paper
• Refractory angina - current therapeutic challenge

  2007cites this paper
• Trimetazidine inhibits cardiomyocyte apoptosis in a rabbit model of ischemia-reperfusion.

  2007cites this paper
• A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure.

  2006cites this paper
• Metabolic therapy for patients with diabetes mellitus and coronary artery disease.

  2006cites this paper
• Role of trimetazidine in management of ischemic cardiomyopathy.

  2006cites this paper
• Suppression of angioplasty-related inflammation by pre-procedural treatment with trimetazidine.

  2006cites this paper
• Randomized Clinical Trial of rimetazidine , a Partial Free Fatty Acid xidation Inhibitor , in Patients With Heart Failure

  2006cites this paper
• Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure.

  2006cites this paper
• Effect of selective 3-ketoacyl coenzyme A thiolase inhibition on glucose metabolism in cardiac patients

  2006cites this paper
• From recurrent ischemia to ischemic heart failure: new data on

  2006cites this paper
• The anti-ischemic effect of trimetazidine in patients with postprandial myocardial ischemia is unrelated to meal composition.

  2006cites this paper
• Lipotoxicity in cardiac and skeletal muscle

  2006cites this paper
• Modulation of metabolic changes in patients with heart failure by selective inhibition of 3-ketoacyl coenzyme A thiolase

  2006cites this paper
• Angina : identifying and managing the patient at risk -

  2005cites this paper
• Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy

  2005cites this paper
• Meeting the challenge of chronic ischaemic heart disease with trimetazidine

  2005cites this paper
• Trimetazidine for stable angina.

  2005cites this paper
• Effects of Trimetazidine on Myocardial Perfusion and the Contractile Response of Chronically Dysfunctional Myocardium in Ischemic Cardiomyopathy

  2005cites this paper
• Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease.

  2004cites this paper
• Metabolic manipulation in ischaemic heart disease, a novel approach to treatment.

  2004cites this paper
• Utilidad de la trimetazidina en la lesión por isquemia-reperfusión. Estudio experimental en un modelo canino de aturdimiento miocárdico

  2004cites this paper
• Effects of Trimetazidine on Left Ventricular Function in Patients with Type 2 Diabetes and Heart Failure

  2004cites this paper
• [Clinical and hemodynamic efficacy of selective beta-blocker bisoprolol and cytoprotector trimetazidine in the treatment of chronic cardiac failure in patients with ischemic heart disease].

  2004cites this paper
• Clinical benefits of trimetazidine in patients with recurrent angina.

  2004cites this paper
• Efficacy and tolerability of trimetazidine in stable angina: a meta-analysis of randomized, double-blind, controlled trials

  2003cites this paper
• Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study

  2003cites this paper
• Cytoprotekcja w leczeniu choroby wieńcowej. Znaczenie leków o modyfikowanym uwalnianiu

  2003cites this paper
• Myocardial Cytoprotection by Trimetazidine Against Anthracycline-Induced Cardiotoxicity in Anticancer Chemotherapy

  2003cites this paper
• Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy.

  2003cites this paper